Phase 3 Study of US-ATG-F to Prevent Moderate to Severe Chronic GVHD in Adult Acute Myeloid Leukemia, Acute Lymphoid Leukemia, and Myelodysplastic Syndrome Patients After Allogeneic Stem Cell Transplantation From Unrelated Donors

Location:

Rochester, Minn.

Trial status:
Open for Enrollment
Why is this study being done?

This study is randomized, prospective, double-blind, placebo-controlled, phase 3 study evaluating the prevention of moderate to severe chronic GVHD in patients undergoing bone marrow or peripheral blood stem cell transplantation from matched, unrelated donors for acute leukemia and myelodysplastic syndrome during the first year after transplant. Patients meeting all the inclusion and none of the exclusion criteria will be randomized (1:1). All patients will receive premedication and study drug 3 days prior to transplantation.

Who is eligible to participate?

Key Inclusion Criteria: - Patients designated to undergo allogeneic peripheral blood or bone marrow stem cell transplantation following the diagnosis of one of the primary diseases in early or intermediate disease status (i.e., acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome) - Patients with an unrelated HLA-A,-B, -C and -DRBI matched donor - Patients with a Karnofsky Performance Score ≥ 70% Key Exclusion Criteria: - Clinically significant concomitant diseases (i.e., cardiac, pulmonary, renal and CNS) - Bacterial, viral, or fungal infections - Known positive for Hepatitis B surfaces antigen, or Hepatitis C antibody, or who have been tested positive for HIV - Patients with any concurrent malignancy. Cancer treated with curative intent < 5 years previously will not be allowed except for patients with resected basal cell carcinoma or treated cervical carcinoma in situ - Known contraindications to the administration of rabbit immunoglobulin antibodies - Hypersensitivity to methylprednisolone, tacrolimus, methotrexate or any excipients contains in these products

Last updated:
11/26/2013
NCT ID:
NCT01295710